Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.54 |
| ▸ | RICTOR | Q6R327 | 3/20 | 0.54 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.54 |
| ▸ | MAPKAP1 | Q9BPZ7 | 3/20 | 0.54 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409520 | 1.00 | MTOR (0.56) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL29727937 | 1.00 | MTOR (0.56) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL28977909 | 1.00 | MTOR (0.56) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL19629401 | 0.92 | MTOR (0.53) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL21029958 | 0.92 | MTOR (0.53) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL20692837 | 0.92 | MTOR (0.53) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL21394004 | 0.92 | MTOR (0.53) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL10124249 | 0.89 | MTOR (0.50) | MTORPIK3CAPIK3R1 | |
| SCHEMBL14811270 | 0.89 | MTOR (0.50) | MTORPIK3CAPIK3R1 | |
| SCHEMBL14811271 | 0.89 | MTOR (0.50) | MTORPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2022-05-05 | — | — | US | disclosed |
| WO-2019101853-A1 | TREATMENT OF SKIN DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | MTOR 4473/4885PIK3CA 4513/4885RICTOR 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.